PharmaSphere: US Healthcare Policy Update – Impact Analysis of the Affordable Care Act on Stakeholders...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Report Scope 10
2.2 Upcoming Related Reports 11
2.3 Recently Published Reports 11
3 Industry Dynamics 12
3.1 Soaring Expenditures in the US Healthcare System 12
3.1.1 US Healthcare Spending and Funding: Following the Healthcare Dollars 15
3.1.2 Generics: A Cost-Effective Option 20
3.2 Biosimilars: Proponents and Opponents 21
3.2.1 State Legislative Tussles 21
3.3 The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 23
4 US Healthcare Reform 24
4.1 Overview 24
4.2 The Individual Mandate Provision 25
4.2.1 The US Supreme Court Ruling 26
4.3 Affordable Care Act Implementation Timeline 27
4.3.1 2010: Provisions Primarily Targeted at Increasing Healthcare Coverage 27
4.3.2 2011: Additional Rebates for Pharma 31
4.3.3 2012: The Emergence of Accountable Care Organizations 35
4.3.4 What’s New in 2013? 37
4.3.5 Beyond 2013 (2014-2018) 39
5 Stakeholders’ Analysis 42
5.1 Budgetary Impact of Insurance Coverage Provisions in the Affordable Care Act 42
5.2 Providers 45
5.2.1 Medicaid Expansion will increase Patient Volume 45
5.2.2 Looming Healthcare Access Problems? 48
5.2.3 Potential Increase in Quality of Healthcare Services 50
5.3 Payers 51
5.3.1 Increase in Member Volume by Insurance Exchanges 53
5.3.2 New Taxes and Industry Fees on Health Insurance Payers 54
5.3.3 Tiered-Provider Networks Continue to Be a Cost-Containment Strategy 55
5.4 Pharmaceutical Manufacturers 56
5.4.1 The Affordable Care Act: What’s in it for Pharmaceutical Manufacturers? 58
5.4.2 Prescription Drug Spending Will Grow to over $480 Billion by 2021 62
6 Strategic Outlook: The Way Forward 66
6.1 Obamacare Will Get “Rolling” Evaluation 66
6.2 Significant Shuttling Expected within Health Insurance Plans 67
6.3 The Pie Gets Even Bigger for Pharmaceutical Companies 67
6.4 Pharmacies Will Cash-in on Obamacare 69
7 Appendix 70
7.1 Bibliography 70
7.2 Abbreviations 74
7.3 Research Methodology 77
7.3.1 Coverage 77
7.3.2 Secondary Research 77
7.3.3 Expert Panel Validation 78
7.4 About the Authors 79
7.4.1 Analyst 79
7.4.2 Director of Healthcare Industry Dynamics 79
7.4.3 Global Director of Epidemiology and Health Policy 80
7.4.4 Global Head of Healthcare 80
7.5 About the Industry Dynamics Team 81
7.6 About GlobalData 81
7.7 Disclosure Information 81
7.8 Disclaimer 82